submit news    HOME | FEEDBACK  


« NAVIGATION »
NEWS

- Bio/Medicine

- Chemicals

- Defense

- Drug Delivery

- Education

- Electronics

- Energy

- Events

- Grants

- Industry

- Investment

- Litigation

- Materials

- MEMS

- Nanofabrication

- Nanoparticles

- Nanotubes

- Optics

- Partnership

- Patent

- Products

- Quantum dots

- Research

- Smart Dust

- Software
COMPANIES
EVENTS

- Browse by Month

- Current Shows

- Previous Shows

- Submit Events
FEEDBACK
ADVERTISE
LINK TO US

« PARTNERS »
Become A Nanotechwire Partner

FEI Company

Veeco Instruments

Nano Science and Technology Institute

National Nanotechnology Initiative

Nanotechnology at Zyvex

Want to see your Company or Organization listed above? Become A Nanotechwire Partner Today - click here
« NEWSLETTER »



« SEARCH »







11/2/2005 8:44:52 PM
Biophan to Spotlight Nanotechnology and Other Solutions at Rodman & Renshaw Techvest Healthcare Investor Conference

Biophan Technologies, Inc., a developer of next-generation medical technology, has announced that CEO Michael Weiner will present a sampling of the Company's major business and scientific achievements at the Rodman & Renshaw Techvest 7th Annual Healthcare Conference, a high-profile conference for institutional investors and other professionals active in the global biotechnology industry, scheduled for November 7-9 in the New York Palace Hotel in New York City.

Mr. Weiner will present Biophan's nanotechnology-based and other cutting-edge innovations for the medical device industry. He will also discuss revenue implications of the Company's proprietary technologies and solutions.

Among key breakthrough innovations Mr. Weiner will review are solutions that enable vascular stents, vena cava filters and other devices to be accurately imaged with Magnetic Resonance Imaging (MRI) systems. Biophan has developed nanotechnology-based and other proprietary solutions to create "visible stents" that can be imaged with MRI to provide physicians with the ability to easily and safely assess health conditions inside implanted stents, including in-stent restenosis, or to use MRI to image vena cava filters to screen for the presence of blood clots.

Mr. Weiner's presentation is scheduled for Tuesday, November 8, at 12:20 p.m., in the Adams room. Topics Mr. Weiner plans to discuss include the Company's recent progress in development of its intellectual property portfolio, its licensing and equity agreement with medical device manufacturer Boston Scientific, and the Company's recent initiative to enter the estimated $28 billion cardiovascular device marketplace.

Mr. Weiner will outline the Company's various initiatives to ensure the successful monetization of its extensive intellectual property portfolio of more than 156 US patents, licenses and applications, as well as international applications.

"We will discuss our plans to further commercialize our broad IP portfolio and other promising initiatives for high revenue growth opportunities," Mr. Weiner said. "It's extremely valuable for us to reach investment professionals active in the biomedical space, to provide additional exposure regarding our progress in developing biomedical technology innovations to improve healthcare delivery."

Biophan is developing a range of new technologies and solutions to address needs in many multibillion-dollar segments of the global biomedical industry. Among its technologies are solutions to enable medical devices to be safely and/or accurately imaged by Magnetic Resonance Imaging (MRI) systems. Such devices include pacemakers, defibrillators and neurostimulators, which currently are contraindicated for use by MRI - leaving many patients without access to a crucial diagnostic imaging option if and when they need it.

"We anticipate a shift in medical device designs that currently keep MRI out of reach for many patients, and we are proudly at the forefront of that movement," Mr. Weiner added. "Over $12 billion worth of devices are sold every year with shortcomings that make MRI inaccessible for imaging or safety reasons. We believe that these problems must be and can be solved, and we have started to see leading manufacturers such as Boston Scientific taking steps in that direction."

http://www.rodmanandrenshaw.com/

Other Headlines from Biophan ...
 - Biophan Licensor Issued Broad Patent on Nanomagnetic Coatings
 - Biophan Files Drug Delivery Patent for Use of NaturalNano's Halloysite Nanotubes
 - Biophan Files Broad Patent on Use of Halloysite Nanotubes for New Drug Delivery Applications
 - Biophan Joins as Senior Member of Prestigious Engineering Research Center at USC Supported by National Science Foundation
 - Biophan to Receive Nano 50 ``Best of the Best'' Award for Innovation in Nanotechnology at NASA Tech Briefs Conference

More Events Headlines ...
 - Free Keithley Web-Based Seminar Addresses High Brightness LED Test Techniques
 - Leading UK Nano Organisations lend support for NANO Live UK 2011
 - Asylum Research Announces UK User Meeting and Forum June 21, 2011 in Edinburgh
 - CEA-Leti to Present 2 Invited Papers at May 23-26 Conference on Frontiers of Characterization and Metrology for Nanoelectronics
 - UAlbany NanoCollege to host prestigious International Nanotechnology Conference on Communication and Cooperation


« Back To List »

« GET LISTED »
- submit company
- submit news
- submit events
- advertise here

« EVENTS »
- More Events


Copyright 2014 Nanotechwire.com | Privacy Policy |